Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First prospective intergroup translational research trial assessing the potential predictive value of p53 using a functional assay in yeast in patients with locally advanced/inflammatory or large operable breast cancer prospectively randomised to a taxane versus a non taxane regimen.

Next Previous
X
Search
Trial Profile

First prospective intergroup translational research trial assessing the potential predictive value of p53 using a functional assay in yeast in patients with locally advanced/inflammatory or large operable breast cancer prospectively randomised to a taxane versus a non taxane regimen.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Epirubicin (Primary) ; Cyclophosphamide; Cyclophosphamide; Filgrastim; Fluorouracil
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use

    • Most Recent Events

    • 24 Oct 2023 Results of a sub-study with log-term follow-up assessing immune landscape in early BC at a multiplex and spatial resolution using machine learning (ML)-based algorithms and investigating its potential prognostic value using tissue microarrays (TMA) pretreatment samples obtained from patients enrolled in this trial presented at the 48th European Society for Medical Oncology Congress
    • 19 Jul 2012 Actual patient number changed from 798 to 1856 as reporeted by ClinicalTrials.gov.
    • 27 May 2010 Planned end date (6 Nov 2006) added as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top